[go: up one dir, main page]

HN2011001487A - Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y su uso terapeutico - Google Patents

Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y su uso terapeutico

Info

Publication number
HN2011001487A
HN2011001487A HN2011001487A HN2011001487A HN2011001487A HN 2011001487 A HN2011001487 A HN 2011001487A HN 2011001487 A HN2011001487 A HN 2011001487A HN 2011001487 A HN2011001487 A HN 2011001487A HN 2011001487 A HN2011001487 A HN 2011001487A
Authority
HN
Honduras
Prior art keywords
replaced
preparation
tetrahidropiran
pirrolidinona
piperidinona
Prior art date
Application number
HN2011001487A
Other languages
English (en)
Inventor
Zhongli Gao
Ryan Hartung
David Stefany
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HN2011001487A publication Critical patent/HN2011001487A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION DESCRIBE Y REINVINDICA UNA SERIE DE CARBOXAMIDAS N- FENIL-BIPIRROLIDINA SUSTITUIDAS EN FORMULA (I). (I) DONE R1, R2 M,N Y P SON COMO SE DEFINIO ANTERIORMENTE EN ESTE DOCUMENTO. MAS ESPECIFICAMENTE, LOS COMPUESTOS DE ESTA INVENCION SON MODULADORES DE LOS RECEPTORES H3 Y POR LO TANTO, SON UTILES COMO AGENTES FARMACEUTICOS, ESPECIALMENTE EN EL TRATAMIENTO Y/O PREVENCION DE UNA VARIEDAD DE ENFERMEDADES MODULADAS POR LOS RECEPTORES H3, INCLUYENDO ENFERMEDADES ASOCIADAS CON EL SISTEMA NERVIOSO CENTRAL.ADEMAS, LA PRESENTE INVENCION TAMBIEN DESCRIBE METODOS PARA LA PREPARACION DE CARBOXAMIDAS N-FENIL-BIPIRROLIDINA SUSTITUIDAS E INTERMEDIOS PARA ELLO.
HN2011001487A 2008-12-05 2011-06-03 Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y su uso terapeutico HN2011001487A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12008708P 2008-12-05 2008-12-05
FR0955909 2009-08-28

Publications (1)

Publication Number Publication Date
HN2011001487A true HN2011001487A (es) 2013-12-02

Family

ID=41665099

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011001487A HN2011001487A (es) 2008-12-05 2011-06-03 Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y su uso terapeutico

Country Status (27)

Country Link
US (2) US8217052B2 (es)
EP (1) EP2373659B1 (es)
JP (1) JP5410544B2 (es)
KR (1) KR101682889B1 (es)
CN (1) CN102239170B (es)
AR (1) AR074467A1 (es)
AU (1) AU2009322243B2 (es)
CA (1) CA2745715C (es)
CO (1) CO6390059A2 (es)
CR (1) CR20110289A (es)
DO (1) DOP2011000166A (es)
EC (1) ECSP11011109A (es)
ES (1) ES2507574T3 (es)
HN (1) HN2011001487A (es)
IL (1) IL213292A (es)
MA (1) MA32945B1 (es)
MX (1) MX2011004791A (es)
MY (1) MY150789A (es)
NZ (1) NZ593150A (es)
PA (1) PA8852301A1 (es)
PE (1) PE20110773A1 (es)
RU (1) RU2519778C2 (es)
TN (1) TN2011000223A1 (es)
TW (1) TWI441826B (es)
UA (1) UA104880C2 (es)
WO (1) WO2010065798A1 (es)
ZA (1) ZA201103261B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
JP5833105B2 (ja) * 2010-05-11 2015-12-16 サノフイ 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
EP2569303A1 (en) 2010-05-11 2013-03-20 Sanofi Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
EP2569280B1 (en) * 2010-05-11 2015-02-25 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
JP2013526530A (ja) * 2010-05-11 2013-06-24 サノフイ 置換されたｎ−フェニルスピロラクタムビピロリジン、その製造及び治療上の使用
TW201206910A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
JP2013526529A (ja) 2010-05-11 2013-06-24 サノフイ 置換されたｎ−ヘテロアリールビピロリジンカルボキサミド、その製造及び治療上の使用
EP2569305B1 (en) 2010-05-11 2015-04-08 Sanofi Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256276A (en) * 1961-02-17 1966-06-14 Geschickter Fund Med Res Substituted spiroimides
US3258276A (en) 1964-04-06 1966-06-28 Charles E Murcott Utility chair
WO2003031432A1 (en) * 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US6889262B1 (en) 2002-06-26 2005-05-03 Advanced Micro Devices, Inc. Direct transaction mode for peripheral devices
AU2003287206A1 (en) 2002-10-23 2004-05-13 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
ATE547404T1 (de) * 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
US8008296B2 (en) * 2005-07-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
WO2007055418A1 (ja) * 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. アザ置換スピロ誘導体
CN101331131A (zh) 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007135111A1 (en) * 2006-05-23 2007-11-29 High Point Pharmaceuticals, Llc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
EP2049473A2 (en) 2006-06-29 2009-04-22 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
US20100317679A1 (en) 2007-09-21 2010-12-16 Ligand Pharmaceuticals, Inc. Substituted aryl-fused spirocyclic amines
NZ584691A (en) 2007-10-17 2011-09-30 Sanofi Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
PT2212283E (pt) * 2007-10-17 2011-11-03 Sanofi Sa Carboxamidas de n-fenil-bipirrolidina substituídas e sua utilização terapêutica
HRP20110953T1 (hr) 2007-10-17 2012-01-31 Sanofi Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.

Also Published As

Publication number Publication date
IL213292A0 (en) 2011-07-31
MA32945B1 (fr) 2012-01-02
DOP2011000166A (es) 2011-10-31
MX2011004791A (es) 2011-05-30
AU2009322243B2 (en) 2015-07-16
TW201033219A (en) 2010-09-16
TWI441826B (zh) 2014-06-21
PE20110773A1 (es) 2011-10-26
KR101682889B1 (ko) 2016-12-06
ES2507574T3 (es) 2014-10-15
CA2745715A1 (en) 2010-06-10
KR20110095911A (ko) 2011-08-25
TN2011000223A1 (en) 2012-12-17
CO6390059A2 (es) 2012-02-29
CA2745715C (en) 2014-01-28
PA8852301A1 (es) 2010-07-27
ZA201103261B (en) 2012-01-25
US8383814B2 (en) 2013-02-26
CR20110289A (es) 2011-09-21
AU2009322243A1 (en) 2011-06-23
ECSP11011109A (es) 2011-11-30
US20110251225A1 (en) 2011-10-13
WO2010065798A1 (en) 2010-06-10
CN102239170B (zh) 2014-08-20
EP2373659A1 (en) 2011-10-12
UA104880C2 (uk) 2014-03-25
AR074467A1 (es) 2011-01-19
US20120238757A1 (en) 2012-09-20
RU2011127382A (ru) 2013-01-10
MY150789A (en) 2014-02-28
EP2373659B1 (en) 2014-07-30
RU2519778C2 (ru) 2014-06-20
US8217052B2 (en) 2012-07-10
CN102239170A (zh) 2011-11-09
NZ593150A (en) 2012-10-26
JP2012511011A (ja) 2012-05-17
JP5410544B2 (ja) 2014-02-05
IL213292A (en) 2014-01-30

Similar Documents

Publication Publication Date Title
ECSP11011108A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
HN2011001487A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y su uso terapeutico
ECSP10010722A (es) Compuestos orgánicos
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
NI200900186A (es) Aril pirrolidinas insecticidas.
CY1112083T1 (el) Υποκαθιστουμενα ν-φαινυλο-διπυρρολιδινο καρβοξαμιδια και η θεραπευτικη τους χρηση
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
NI201100162A (es) Derivados de indol como antagonistas del receptor crth2
EA201170772A1 (ru) Органические соединения
ECSP099553A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
UY30723A1 (es) Compuestos de biciclocarboxiamida sustituidos
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
CY1112683T1 (el) Υποκατεστημενες καρβοξαμιδες ν-φαινυλ-διπυρρολιδινης και θεραπευτικες χρησεις τους
CY1112391T1 (el) Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CO6341625A2 (es) Derivados de indol como agentes anticáncer
UY30451A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroéteres (18-metil-19-nor-20-espirox-4-en-3-onas),ase como preparaciones farmacéuticas que lo contienen.
PE20070246A1 (es) Compuestos de pirazolina sustituidos como moduladores del receptor cb1 y su preparacion
PA8720601A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
UY32294A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
NI201100094A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico.
NI201100090A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico.